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Abstract

PREHOSPITAL TROPONIN TESTING PROTOCOL FOR ACCELERATED
DIAGNOSIS AND EARLY INTERVENTION IN CHEST PAIN PATIENTS
Ronald D. Meador
DNP Scholarly Project Chair: Sandra Peterson, DNP
The University of Texas at Tyler
May 2019
Non-ST elevation acute coronary syndromes (NSTE-ACS) have significant
morbidity and mortality rates despite the progress made in diagnosis and management
and represent a significant public health burden in the United States. Lengthy diagnostic
algorithms contribute to emergency department over-crowding, increased health care
costs, and adverse patient outcomes. A troponin assay instituted earlier in the diagnostic
pathway of patients with chest pain suspected of NSTE-ACS will reduce time to
definitive diagnosis and medical intervention. This will improve patient outcomes,
decrease emergency department crowding through improved ED workflow, and reduce
the economic burden. The Star Model of Knowledge Transformation was used to guide
an understanding of the cycles, nature, and characteristics of knowledge of NSTE-ACS,
organize previous and current concepts of improving care, and provided the framework to
guide design, implementation, evaluation and sustainability. The Prehospital Troponin
Testing Protocol (PHTTP) instituted a point-of-care troponin assay in the ambulances of
the Plainview Fire-EMS department and used this value in an accelerated diagnostic
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pathway in the Covenant Plainview Emergency Department. The PHTTP reduced the
time to first troponin from 79 minutes (1.32 hours) to 22 minutes (0.37 hours) and time to
disposition of patients from 191.00 minutes (3.18 hour) to 150.04 minutes (2.50 hours).
Time to first troponin was reduced by 47.00 minutes (0.78 hours) and length of stay was
reduced by 40.96 minutes (0.67 hours). The prehospital scene time was increased by 1
minute which was not statistically significant.
Keywords: non-ST segment elevation acute coronary syndrome, prehospital
troponin, accelerated diagnostic pathway, and emergency department overcrowding.
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Chapter 1
Development of the Clinical Question and Problem Identification
Introduction
The Prehospital Troponin Testing Protocol (PHTTP) for Accelerated Diagnosis
and Early Intervention in Chest Pain Patients is an inter-professional, collaborative,
biphasic evidenced-based practice implementation project (EPIP). The PHTTP is interprofessional as it requires the collaborative practice of prehospital personnel (Emergency
Medical Technicians and Paramedics) and clinical emergency medicine staff (nurses,
advanced practice providers, and physicians). The PHTTP has two distinct phases: the
prehospital phase and the clinical emergency medicine phase with the collective goal of
improving patient outcomes and improving ED workflow. This protocol is designed to
concurrently improve patient outcomes and emergency department workflow without a
significant increase in prehospital scene times. These improvements are accomplished
through the utilization of a prehospital point-of-care troponin assay incorporated into an
accelerated diagnostic algorithm for patients with chest pain who present to the
emergency department (ED) via emergency medical services (EMS).
Background and Significance
Non-ST Elevation Acute Coronary Syndrome(NSTE-ACS) is one of three acute
coronary syndromes (ACS) without significant ST segment elevations demonstrated on
the electrocardiogram (ECG). NSTE-ACS is caused by a partial occlusion of a coronary
artery. This patient population forms approximately two-thirds of all hospital admissions

for ACS in the United States each year and is associated with an in-hospital mortality of
5% (Bob-Manual, 2017). According to the American College of Cardiology/American
Heart Association (ACC/AHA), despite the progress made in recent years in the
diagnosis and management of NSTE-ACS, the rate of morbidity remains high and the
rate of mortality is significant (Rodriguez, 2016) (see Appendix A). Previous research
demonstrates the utilization of a prehospital testing protocol will reduce the public health
burden of NSTE-ACS by decreasing the time required for final diagnosis; and utilization
of early interventional strategies, and thus decreasing the percentage of major adverse
cardiac events (MACE) over time.
In the United States (US), an NSTE-ACS event occurs every 25 seconds and an
NSTE-ACS-related death occurs every minute (Amsterdam, 2014). Further, 9-19% of
patients who experience an NSTE-ACS event die in the first six months after diagnosis
and half of these deaths occur within the first 30 days (Amsterdam, 2014). There are two
types of ACS events: (1) NSTE-ACS, and (2) unstable angina (UA). The economic
impact of all NSTE-ACS-related causes of morbidity and mortality is estimated to $141
trillion annually (Vendanthon, 2014). Amsterdam (2014) estimated that more than
780,000 individuals will have an ACS event annually and approximately 71% of them
will be diagnosed as NSTE-ACS. The diagnosis and treatment of NSTE-ACS represents
a significant public health burden in the United States (Amsterdam, 2014). Emergency
departments (ED) in the US are currently in crisis due to overcrowding and diagnostic
delays (Barish, 2012). The current utilization of lengthy NSTE-ACS diagnostic
algorithms contributes to these extended lengths of stay (LOS), poor ED workflow, and
the overcrowding (Barish, 2012). Cullen (2013) found prolonged assessment of patients
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with chest pain who were suspected of ACS; contributed to overcrowding, increased
costs, and adverse patient outcomes, including increased incidence of MACE. As ED
overcrowding adversely impacts patient morbidity and mortality, measures to decrease
ED LOS and improve ED workflow have been advocated (Meek, 2016).
Amsterdam (2014) demonstrated that a delay in the diagnosis of NSTE-ACS is
associated with increases in morbidity and mortality from MACE. Darling (2013)
demonstrated that patients with acute myocardial infarction (AMI) experienced a better
post-discharge prognosis than those with NSTE-ACS. The factors associated with
increased mortality for each of these patient groups were slightly distinct. Therefore,
NSTE-ACS events represent a significant economic and health burden in the US and
much of this burden is due to the time required to diagnose and initiate appropriate
treatments using current diagnostic algorithms.
The incidence of NSTE-ACS increases significantly after age 18 (Amsterdam,
2014). The American Heart Association (AHA) reported the age range for NSTE-ACS
events in the United States is 56-79 years with a median age of 68. The ratio of males to
females is 3:2. NSTE-ACS is more frequent in African Americans than Caucasians. The
rate of NSTE-ACS also increases proportionally with the number of comorbidities
(Amsterdam, 2014). Patients at greater risk for NSTE-ACS events present either the
following major risk factors or a combination of them: high-serum cholesterol,
hypertension, diabetes mellitus, obesity, and smoking. Moreover, 25% of NSTE-ACS
patients have diabetes (Amsterdam, 2014).
An early invasive treatment strategy can postpone the occurrence of death or next
acute coronary event by an average of 18 months and readmission to the hospital for
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ischemic heart disease by 37 months as compared to a non-invasive strategy in patients
with NSTE-ACS (Wallentin, 2016). Therefore, patients with longer transport time to a
healthcare facility have increased risk of morbidity and mortality from MACE events
than urban patients with shorter transport time.
The American College of Cardiology/American Heart Association, in their most
current guidelines published in 2014, recommend that the utilization of early invasive
strategies (EIS) is likely to improve patient outcomes (Khera, 2014). Morrow (2001)
demonstrated that patients with clinically documented NSTE-ACS derive significant
clinical benefit from EIS. Serial cardiac troponins should be obtained upon presentation
of chest pain in patients after 90 minutes to two hours if using high-sensitivity troponin
assays, and three hours later, if using non-high-sensitivity troponin assays (Amsterdam,
2014). This 90-minute to 3-hour algorithm contributes to the ED LOS, time required for
definitive diagnosis, and associated costs (Luca, 2016). Khera (2014) in a meta-analysis
of randomized, controlled trials demonstrated a consistent benefit in the utilization of EIS
in the setting of NSTE-ACS, especially in setting high-risk populations. They further
concluded that the earlier these strategies are employed, the better the patient outcomes
are. Layfield (2014), in a systematic review, found that serial cardiac troponin sampling
with one sample at presentation and at least one additional sample collected two hours
later was necessary to identify a rise or fall in the troponin level. Testing with highsensitivity cardiac troponin assays without other biomarkers at presentation and then at
90 minutes to two hours is the current testing algorithm for most accurate and timely
NSTE-ACS diagnosis. Therefore, the PHTTP can decrease the diagnostic interval of
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NSTE-ACS and initiate EIS sooner by obtaining the first troponin value in the ambulance
instead of waiting until the patient arrives in the ED and delaying the diagnosis.
Troponin is a regulatory protein complex of striated cardiac and skeletal
muscle. The troponin complex is divided into three subunits: Troponin C (TnC),
Troponin I (TnI), and Troponin T (TnT). TnC is tissue-specific to skeletal muscle
damage and TnI and TnT are tissue-specific to myocardial damage (Vasile, 2009). TnI
and TnT are the standard cardiac diagnostic biomarkers referred to as cTnI and cTnT,
respectively (Mahajan, 2011). Free forms of cTnI are released in the early stages of
ischemia and bound forms are released from degradation as ischemia progresses (Vasile,
2009). Therefore, the PHTTP will utilize cTnI as the biomarker because of its increased
specificity to myocardial ischemia.
The development of sensitive cardiac Troponin I (cTnI) assays permits the
detection of lower concentrations of cTnI earlier as it begins to rise within three to four
hours after the onset of myocardial injury (Sherwood, 2014). Sherwood (2014)
demonstrated that the use of cTnI assays facilitates earlier diagnosis of NSTE-ACS and
improves risk stratification. Borna (2016) demonstrated that cTnI testing was a superior
biomarker to diagnose NSTE-ACS within three hours of the patients presenting to the ED
with chest pain. POC testing equipment has provided portability and reliability to
troponin evaluation which provides a stable platform to utilize in the prehospital setting.
Therefore, the use of prehospital cTnI POC testing has the potential to reduce the
diagnostic timeframe and streamline the care of NSTE-ACS patients beginning earlier in
the treatment pathway. This reduction in diagnostic time will facilitate the utilization of
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EIS and over time reduce the impact of MACE events following the diagnosis of NSTEACS.
Roffi (2015) reported chest discomfort as the leading symptom that initiates the
diagnostic and therapeutic cascade in patients with suspected ACS. Patients reporting
chest pain frequently use emergency medical services (EMS) for transport to the ED. For
patients reporting chest pain due to NSTE-ACS, in the prehospital setting, current clinical
guidelines offer in-hospital risk stratification and management as opposed to
straightforward prehospital strategy for diagnosis, medication regimen, and logistics
(Ishak, 2014).
Stengaard (2013) validated the feasibility of using prehospital troponin
quantitative POC cardiac troponin testing and its capacity to predict mortality. They
additionally demonstrated the potential to accelerate triage and diagnosis of NSTE-ACS
patients using POC troponin testing is feasible. Stengaard also found that the diagnosis
of NSTE-ACS in the prehospital phase impacts the mode of revascularization, is
associated with earlier revascularization, and results in shorter hospital stays and
improved long term outcomes. Venturini (2013) found that there was no statistical
difference between prehospital and ED troponin results, thus concluding that POC-cTn is
a stable and accurate biomarker testing platform (see Appendix B). Despite being used in
a moving ambulance, POC testing reliably provided accurate results of troponin assays as
compared to the results of those performed in the ED. Ezekowitz (2015) found that
prehospital POC-troponin testing decreased the time from first medical contact (FMC) to
final disposition in the ED by 0.29 hours. Ezekowitz additionally postulated that this
0.29-hour reduction time to final diagnosis within an urban setting with short transport
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times could be applied in a rural setting with long transport times and the effect could be
potentially magnified. Ezekowitz (2015) and Venturini (2013) demonstrated that
prehospital troponin is a reliable diagnostic platform and has the potential to reduce
diagnostic time for NSTE-ACS patients. The utilization of prehospital personnel to use
POC devices to measure troponin levels during transport of patients to the ED may result
in earlier diagnosis of NSTE-ACS (Venturini, 2013). Patel (2012) determined average
ground EMS transport times of 43.3 minutes (urban) and 57.6 minutes (rural). Sorenson
(2011) indicated that implementation of quantitative prehospital troponin testing by
paramedics is feasible and effective. Therefore, prehospital POC testing can expedite the
diagnosis of NSTE-ACS by reducing the two-hour ED diagnostic window.
Conclusions: 1) According to Darling (2013), NSTE-ACS patients have a 16.4%
higher incidence of MACE than AMI patients, 2) high-sensitivity troponin is the
biomarker of choice in the diagnosis of NSTE-ACS, 3) accelerated diagnostic pathways
using high-sensitivity troponin testing can reduce the time to diagnosis of NSTE-ACS, 4)
prehospital troponin testing can reduce the prevalence of MACE events by reducing time
by utilizing EIS, 5) the use of prehospital troponin testing along with an accelerated
diagnostic protocol can further reduce diagnostic time by as much as 0.29 hours in the
urban setting according Ezekowitz (2015) and potentially higher in the rural setting, 6)
treatment delays from current diagnostic pathways results in greater MACE for NSTEACS patients than AMI patients (see Appendix B). The use of prehospital troponin
testing with an accelerated diagnostic protocol can further reduce diagnostic time by as
much as 0.29 hours in the urban setting and potentially higher in the rural setting
(Ezekowitz, 2015). Therefore, prehospital POC troponin testing can decrease the
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diagnosing time of NSTE-ACS by a minimum of 0.29 hours and concomitantly reduce
the incidence of MACE through utilization of NSTE-ACS patients from 12% to 8.9%
MACE at 10 months according to Cantor (2005). In summary, based on the background
evidence referenced, NSTE-ACS represent a significant public health burden and the
utilization of a PHTTP can reduce this burden.
Development of the Clinical Question/Problem – PICOT Question
In patients with chest pain suspected of non-ST segments acute coronary
syndromes (P), how does prehospital troponin testing (I), compared to no prehospital
troponin testing affect time to diagnosis of acute coronary syndrome (O1) and utilization
of early interventional strategies (O2), associated morbidities (O3), major adverse cardiac
events (04), ED workflow and overcrowding (O5), and reduce economic burden (O6)
over a thirty-day period (T)?
The Star Model of Knowledge Transformation
The Star Model of Knowledge Transformation is a model for understanding the
cycles, nature, and characteristics of knowledge that are used in various aspects of
evidence-based practice (Stevens, 2012). The Star Model organizes previous and current
concepts of improving care and provides the framework to organize evidence-based
practice (EBP) processes as follows: Star Point 1 (Discovery Research): This step
presents information from the studies in the Evidence Table. Star Point 2 (Evidence
Summary): Evidence summary is the first unique step in EBP and its purpose is to
synthesize the body or research knowledge into a compact, meaningful statement of the
state of the science. This stage reduces large quantities of information into a manageable
form to establish generalizability across participants, setting, treatment variations, and
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study design. Star Point 3 (Translation to Guidelines): The goal of the translation stage is
to provide a useful and relevant package of summarized evidence to clinicians and clients
in a form that suits the time, cost, and care standard. Based on this package of evidence,
recommendations are made as clinical practice guidelines and may represent clinical
pathway, protocols, and algorithms. Star Point 4 (Practice Integrations): This step
involves changing both individual and organizational practices through formal and
informal channels. Star Point 5 (Process, Outcome Evaluation): This is the final stage in
knowledge translation where the impact of the EBP project on patient health outcomes,
provider and patient satisfaction, efficacy, efficiency, economic analysis, and health
status impact is evaluated (Stevens, 2012). The Star Model provides a systematic
framework for the initiation of a PHTTP for an EBP change based on the best available
evidence.
Systematic Search for Evidence Process and Results
A systematic search was conducted using three primary electronic databases: 1)
the Cumulative Index to Nursing and Allied Health (CINAHL), 2) the Cochrane
Database of Systematic Reviews (CDSR) and 3) PubMed. Three major searches were
conducted in the CINAHL database: keyword, title, and subject heading. Two major
searches were conducted in the Cochrane Database: combination (title/abstract/keyword)
and keyword. Five major searches were performed in PubMed: MeSH terms, MeSH
major topics, MeSH title title/abstract, and title (see Appendix C).
The search across all databases was performed with terms from the PICOT
question and their major synonyms, acronyms, coined phrases, and brand names. These
terms include the following: acute coronary syndromes, ACS, non-ST segment elevation
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myocardial infarction, NSTEMI, non-ST segment elevation acute coronary syndrome,
NSTE-ACS, troponin, high sensitivity troponin, point of care troponin, prehospital
troponin, early invasive strategies, and EIS. The only limitations implemented in the
searches were English and humans. Appendix C demonstrates the systematic search
through all three databases using the terms previously listed from the PICOT question.
Articles containing any of the following variables were deemed eligible for
review related to the PICOT question: prehospital troponin testing, POC troponin testing,
diagnostic windows for ACS diagnosis, NSTE-ACS morbidity and mortality, early EIS
for ACS, accelerated diagnostic protocols for diagnosis of ACS, cardiac biomarkers for
diagnosis of ACS, PCI strategies for ACS, treatment of hospitalized patients diagnosed
with ACS, effectiveness of thrombolytics and percutaneous coronary intervention in
ACS, MACE scoring of ACS patients, reliability of prehospital POC systems, and
diagnostic delays in ACS patients. Articles were excluded if they contained the
following variables: less than eighteen years of age, chest pain of non-cardiac origin,
symptoms greater than 12 hours from onset, AMI without mention of NSTE-ACS, ACS
without specific mention of NSTE-ACS, diagnostic pathways exceeding two hours,
diagnosis without mention of troponin, prehospital transport via aeromedical services, inpatient management without mention of emergency department treatment, and articles
without mention of outcomes related to ACS patients.
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Figure 1. Systematic Search Results Flowchart
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Conclusion
NSTE-ACS events represent a significant public health burden to not only the
patients but also the health care systems that they access to seek care. NSTE-ACS
events, despite advances in diagnostic pathways and interventional strategies, continue to
have high morbidity and mortality rate than STE-ACS events. EMS are often the first
medical providers who contact chest pain patients and represent an untapped resource to
make improvements in patient outcomes using new technologies. These medical
providers in the early assessment of cardiac biomarkers are an underutilized system to
improve the outcomes of patients and the overall health care system.
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Chapter 2
Critical Appraisal of the Evidence, Model, and Plan
Appraisal of Evidence
The scholarly articles obtained from the systematic search discussed in Chapter
One were evaluated using the critical appraisal process to identify the strengths and
weaknesses to assess the usefulness and validity of the research findings. Initially, a
General Appraisal Overview (GAO) was completed, followed by a Rapid Critical
Appraisal (RCA) to assess validity, reliability, and applicability. One article was
excluded after completing the critical appraisal process as the study was incomplete and
therefore the validity of proposed outcomes could not be validated, thus impairing its
reliability and applicability to this project. The remaining 10 articles were determined to
have conclusions adequately supported by the data presented and data evaluated had
validity, reliability, and applicability to this project.
There were no ethical concerns resulting in the exclusion of any additional
studies. All studies demonstrated (where applicable) that 1) Respect for Autonomy—
participants freely participated of independent choice without evidence of coercion and
informed consent was obtained from all participants, 2) Non-maleficence—there was no
harm or the least possible harm to reach a beneficial outcome, 3) Beneficence—
interventions are to benefit individuals outcomes, 4) Justice—fair selection of study
participants without bias, 5) Equipoise—genuine uncertainty when assigning patients to
treatment arms, 6) bias free trial in case of industry funded research, and 7) appropriate

Institutional Review Board (IRB) approval was acquired or waived as required.
Further, 36 articles were identified from the search of CINAHL, CDSR, and
PubMed and the Abilene Christian University Library in Abilene, Texas that initially met
criteria of the PICOT question. Additionally, two non-full text and three duplicate
records were removed, yielding 31 articles for review using inclusion and exclusion
criteria as previously discussed. After applying the inclusion/exclusion criteria, 20
articles were excluded. One article was removed article during the critical appraisal
process as the study was incomplete at the time of publication and therefore reliable
outcome data was not present. Therefore, the final yield was 10 articles included in the
body of evidence (36 – 2 – 3 – 20 – 1 = 10).
Evaluation of the Body of Evidence
Ten studies were used to provide the body of evidence to address the components
of the PICOT question. These studies supported the assertion that the implementation of
a high-sensitivity troponin testing protocol can reduce the time to final diagnosis of
NSTE-ACS, concomitantly reduce the time to EIS and therefore reduce the incidence of
MACE and improve outcomes of patients with chest pain encountered in out-of-hospital
setting. The following components of the PICOT question will be validated with the
evidence compiled: 1) POC cTnI is the assay of choice for this implementation, 2) the
appropriate diagnostic window is 90 minutes to two hours, 3) utilization of prehospital
POC cTnI is accurate and reliable, and 4) reduction in the time from first medical contact
to diagnosis of NSTE-ACS in patients with chest pain reduces the duration of the
utilization of EIS, and 5) the utilization of EIS earlier in the diagnostic pathway of NSTEACS patients reduces MACE and improves patient outcomes.
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The Study Methodology Synthesis Table in Appendix D demonstrates that cTnI is
the assay of choice to utilize in the project implementation. Studies of Vasile (2009) and
Sherwood (2014) demonstrated that cTnI assays permits the detection of lower
concentrations of cTnI earlier than cTnT as cTnI begins to rise within three to four hours
after the onset of myocardial injury. The 12 studies listed in the Study Methodology
Synthesis Table in Appendix E demonstrated that the use of prehospital POC cTnI is a
statistically reliable assay method to use on patients with chest pain. The 90 minute to
two hour diagnostic testing window was an effective interval to make accurate diagnostic
decisions regarding patients with chest pain. Therefore, the included studies support the
assertion that the use of prehospital POC cTnI is a reliable methodology to diagnose
NSTE-ACS in patients encountered outside the hospital ED.
The Outcome Synthesis Table in Appendix F demonstrates the evidence reviewed
supports the PICOT question assertion that reducing the time to diagnosis of NSTE-ACS
improves patient outcomes. The studies included demonstrate that a prehospital POC
cTnI protocol can reduce the time to diagnosis of NSTE-ACS in patients with chest pain
encountered outside the ED setting by reducing the time from first medical contact
(FMC) to first troponin (T1). Ezekowitz (2015) demonstrated that prehospital POCTroponin testing decreased the time from FMC to final disposition in the ED by 0.29
hours. Therefore, evidence suggests that the initiation of a prehospital POC cTnI testing
protocol will reduce the duration of diagnosis of NSTE-ACS in patients with chest pain
suspected of NSTE-ACS.
The Outcome Synthesis Table in Appendix F additionally demonstrates that as the
time from FMC to T1 is decreased, the remainder of the time variables are concomitantly
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reduced. The evidence demonstrates that if FMC to T1 is reduced then T1 to T2 is
reduced, T2 to diagnosis is reduced, diagnosis to EIS is reduced. As the time from FMC
to EIS is reduced, the evidence demonstrates that MACE is reduced. Therefore, the
evidence demonstrates that prehospital POC cTnI testing reduces time from FMC to
diagnosis and EIS.
Synthesis and Recommendation Based of the Body of Evidence
Institute a pre-hospital POC cTnI testing EPIP using an accelerated diagnostic
protocol to reduce to LOS of chest pain patients that present to the ED via EMS with
complaints of chest pain of suspected NSTE-ACS. The evidence demonstrated that
prehospital POC troponin testing is a valid and reliable method which has been
successful in reducing the time to disposition in a large urban emergency department.
This reduction in disposition time can reduce ED LOS, improve ED workflow and reduce
ED overcrowding, and reduce the morbidity and mortality rate of NSTE-ACS
occurrences longitudinally.
Proposed Evidence-based Implementation Project and Operationalization
The Theory of Planned Change will be used as a conceptual framework to guide
the evidence-based practice (EBP) change to initiate prehospital troponin testing with the
goal of reducing the morbidity and mortality of chest pain patient, suspected of NSTEACS, encountered outside the hospital and time to final disposition (see Appendix
G). Lippitt, Watson, and Westley’s (1958) theory of Planned Change is a seven-step
framework focusing on the role of the change agent throughout the evolution of a change.
Lippitt’s Change Theory (1958) is based on the introduction of an external change agent
designing a program to effect change. This theory focuses on the role and responsibility
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of the change agent where there is a continuous exchange of information throughout the
process. The seven-steps are as follows: 1) Diagnose the problem, 2) Assess the
motivation and capacity for change, 3) Assess the resources and motivation of the change
agent, 4) Choose progressive change objects, 5) Select and clearly understand the role of
the change agents for clear expectations, 6) Maintain the change, and 7) Gradually
terminate from the helping relationship. The seven steps of this theoretical framework
will be utilized in conducting an EBP change project regarding the NSTE-ACS all-cause
mortality. Planned change theory in nursing is an important process ensuring the best
practices are utilized to meet the advancing needs of the health care system and the
patients it serves. Planned change is a purposeful, calculated, and collaborative effort led
by a change agent to effect a positive change within a specific system (Roussel, 2006).
Application of the seven-steps of the TCP: 1) Problem: High > 30 day post
NSTE-ACS mortality (see Appendix G)/ED overcrowding, 2) Assess Motivation: Are the
EMS systems and ED willing to make a change? Are the EMS and ED systems willing
to collaborate with each other? Is the return on investment substantial enough to justify
the initial cost? Is the ED system willing to accept a troponin value obtained outside of
the ED? Is the cardiology service or hospitalist service willing to accept a patient with a
diagnosis of NSTE-ACS with an out-of-hospital troponin? 3) Change Agent and
Motivation: Doctorate of Nursing Practice (DNP)-prepared nurse with emergency
medical experience in both prehospital and ED setting with the best evidence to
demonstrate that by reducing the time from T1 to T2, through the use of a prehospital
troponin protocol, that patient outcomes will be improved, 4) Select Progressive Change
Objects: Initiate prehospital troponin testing protocol that will systematically reduce the
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variables in NSTE-ACS patients (see Appendix G), 5) Choose a Change Agent Role:
DNP collaborative relationship with inter and intra-professional components, 6) Maintain
Change: Assess data (variables listed in Appendix G), re-evaluate (are times decreasing
as expected?) and adapt (if times are not decreasing why are they not and what
intervention needs to be made to improve?), and sustain change (if times are decreasing
and therefore patient outcomes are improving then distribute data to stakeholders for
sustainability), and 7) Termination of Helping Relationship: DNP completes change and
searches for new problems (see Appendix G).
The PHTTP will initiate and evaluate the effectiveness of a prehospital, POC
troponin testing protocol. This project aims to reduce the burden of greater than thirtyday MACE of patients diagnosed with NSTE-ACS. Based on the evidence, the time to
final disposition of chest pain patients encountered outside the hospital is expected to be
reduced by at least 0.29 hours. In addition, the initiation of EIS earlier is expected to
reduce the MACE in NSTE-ACS patients (see Appendix F). These results will be
evaluated to determine if this project was as effective as hypothesized in the literature.
Conclusion
Based on the synthesis of the best available evidence the implementation of a
prehospital POC cTnI protocol will reduce the time from FMC to disposition of patients
with suspected NSTE-ACS. This reduction in diagnostic time will allow for initiation of
EIS earlier in the treatment pathway of NSTE-ACS patient and improve outcomes by
reducing the incidence of MACE as previously discussed. Based on this synthesis of the
evidence, a prehospital cTnI testing protocol will be designed and a plan for
implementation, evaluation, and sustainability outlined in the following chapters.
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Chapter 3
Project Design and Methodology
This chapter discusses the implementation of the Prehospital Testing Protocol as
guided by the ACE Star Model of Knowledge Transformation. The Star Model is a
simple, parsimonious depiction of the relationships between various stages of knowledge
transformation and places nursing’s previous scientific work within the context of EBP,
serves as an organizer for examining and applying EBP, and mainstreams nursing into the
formal network of EBP (Stevens, 2012). This model was adapted and operationalized for
the purposes of this implementation project. Star Point 1 and 2 were covered in Chapter
1 and 2 and Star Points 3–5 will be covered in this chapter. See Figure 2 on the following
page.

Figure 2. ACE Star Model of the Cycle Knowledge Transformation. Adapted from “ACE
Star Model of EBP: Knowledge transformation,” by K. R. Stevens, 2004, Academic
Center for Evidence-based Practice, 2004 The University of Texas Health Science Center
at San Antonio
Project Design and Methodology Overview
The project protocol will be applied to all patients encountered in the prehospital
setting with chest pain, suggestive of an NSTE-ACS. Each patient will have a serum
troponin level obtained and tested utilizing a POC platform according to the evidence
discussed in Chapter One. T1 will be obtained by prehospital personnel expeditiously
after FMC along with standard interventional therapies of the EMS system utilized in the
protocol implementation. The results of this initial POC test will be provided to the
receiving ED and incorporated into the patients ongoing treatment plan in an accelerated
diagnostic protocol. This accelerated diagnostic protocol will include a T2 value
obtained 90 minutes to two hours after T1 and a final disposition made based on the
46

comparison of the T1 and T2 values. Disposition includes: discharge from the ED,
admission to the hospital, admission to interventional services, or transfer to higher level
of care, if necessary services are not available at the receiving facility.
The population of interest for this project are patients above 18 years, who call
EMS with complaints of chest pain of potential NSTE-ACS origin. Non-cardiac sources
of chest pain include post traumatic chest pain, respiratory chest pain, chest pain of
infective origin, and chest pain of gastrointestinal origin. This will include patients of all
genders, races, and cultural backgrounds.
Fully Operationalized Project
The following diagram in Figure 3 (pages 26 & 27) represents an overview of the
PHTTP Implementation Plan based on the Prehospital Troponin Logic Model (Appendix
H). The specific details of the plan will be outlined following the figure.
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Figure 3. Prehospital Troponin Testing Protocol
48

Figure 4. Prehospital Troponin Testing Protocol (Continued)
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Detailed Implementation Plan
Ethical considerations.
o Ethics of the conducted research —all the studies incorporated in the body
of evidence on which the implementation plan is based on met the
requirements of the ethical research:
•

Scientific value—provided scientific benefit

•

Scientific validity—followed methodological rigor

•

Fair subject selection—ensured appropriate randomization

•

Favorable risk-benefit ratio—evaluates outcomes worth risks

•

Independent review—ensures no conflicts of interest

•

Respect for potential and enrolled subjects—adherence to the
Declaration of Helinski

•

Informed consent—allowing voluntary informed consent to
participate

Ethics of translating the body of evidence into practice.
o

Only the studies that were deemed ethically sound were included in the
body of evidence

o

The evidence was translated directly into the practice protocol without
modification

o

The following questions were addressed in the evidence translation
process to ensure ethical decisions were made:
•

What is the question you want to answer?

•

What are your existing thoughts and feelings about that topic?
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•

How might these thoughts affect your choices about evidence?

•

What can you do to make those choices open and defensible?

Ethics of project planning.
o

Patient confidentiality and safety are of utmost importance

o

All planning was done with the best interest of the patient in mind and the
ways in which the project will improve patient outcomes

o

Financial benefit is considered, but it is not the highest end goal of
implementing this project.

o

Protection of the interests of all stakeholders.

Ethics of implementation of evidence (or not) and use of patient data.
o

No evidence was included in the implementation plan that was previously
not deemed ethical.

o

The integrity of protected health information was maintained.

o

All steps in the implementation process are based on ethical decisionmaking and the concepts of beneficence and non-beneficence.

Ethics of dissemination of the evidence (or not).
o Evidence will be presented objectively with no alterations to potentially
skew the results into a more favorable direction.
o Personal opinions will be withheld from the dissemination of evidence.
o Patient information will be protected.
Ethics of sustainability.
o Does the project fulfill its initial goals?
o What benefits or harms are brought about by sustaining the project?
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o Does the project support the system or context which makes it possible
and meaningful?
o Does the project have the potential to consume all resources prior to
deriving benefit?
Ethics of DNP role delivery.
o Always advocate for the best interests of the patient, their colleagues and
the system as a whole
o Strengthen practice environments by improving practice processes based
on the best evidence
o Strike a balance between personal and professional values in the
implementation of practices
o Ensure that all human rights are protected and that the concept of justice is
always foremost
o Employ strategies to maintain the highest ethical standards
Select project implementation setting.
o Geographical setting with both rural and urban EMS systems and a
regional medical center with interventional cardiology services or transfer
access to a tertiary center or an EMS system that services both rural and
urban population
▪

An urban EMS is a system that operates within the confines of a
city or town with a more concentrated population per square mile

▪

A rural EMS is a system operates outside of the confines of a city
or town with a less concentrated population per square mile.
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▪

The purpose of utilizing both an urban and a rural EMS system is
based on the average difference in transport times

o A tertiary center with interventional cardiology services is one that has a
continuously available cardiac catherization suite with an interventional
cardiologist continuously on call.
Process indicators/Outcomes measures.
o Reduction in time from FMC to T1
o Reduction in facility LOS
o No significant increase in EMS scene times
Anticipated barriers.
o Collaboration between EMS and ED staff and medical directors – This
barrier was addressed through collaborative training and round table
meetings.
o ED physicians, CV Physicians, and Hospitalists unwilling to use a
prehospital troponin value – data on the reliability of prehospital troponin
testing was provided to all ED physician and APP staff
o Administration of either EMS system unwilling to participate in protocol
due to initial equipment costs and training expenses – there was no cost to
the EMS system as all cost was assumed by the project manager.
o Emergency Department unwilling to participate in project – after an
extensive search a willing ED Medical Director and ED manager were
found and provided extensive literature from the EPIP body of evidence.
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Stakeholder Recruitment and Buy-in.

EMS & Hospital
Administration
Medicare/Medicaid
& Private
Insurance

ED Medical
Director/EMS
Medical Director

Texas DSHS

EMS Staff/ED
Staff

Project Manager

Chest Pain Patients
& Family

Laboratory
Services

Cardiology
Services
Hospitalist
Services

Figure 5. Prehospital Troponin Project Stakeholder Interaction

o Organizational Recruitment, Buy-in, and Approval to participate
o Texas Department of State Health Services EMS & Trauma Bureau
o Plainview Fire-EMS
o Covenant Plainview Hospital Administration
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Establishment organizational structure.
o Lead by Project Implementation Manager (DNP-trained Nurse Scholar)
o Includes all components from both EMS systems and receiving hospital
systems
▪

Administrators

▪

Medical Directors

▪

Units

▪

Personnel

Project Manager

Hospital
Administration

EMS
Administration

ED Medical
Director

EMS Medical
Director

ED Director

Cath Lab
Director

Hoapitalist
Director

Lab Director

EMS Director

ED Staff

CATH Lab

Hospitalist

Lab Staff

EMS Staff

Figure 6. Prehospital Troponin Project Organizational Chart

55

TX DSHS

Establishment of committee structure.
o Protocol Design Committee (PDC) creates a consensus protocol to utilize
in the implementation of prehospital troponin testing
o Finance & Purchasing Committee (FPC) explores options for the most
cost effective attainment of the selected POC assay platform either
through grant, direct purchase, or rental and then make necessary
arrangements to acquire the platform
o Training Committee (TC) develops training protocols, training materials,
select sites for training sessions, creating a training calendar, and table top
and simulation trials on the selected and acquired POC platform
o Implementation and Review Committee determines baseline data, selects
exact implementation criteria, oversees implementation, and engages in
process marker monitoring, data review, and protocol adjustment as
needed based on the process markers.
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• Project Manager
• Medical Directors
• Unit Directors

• Project Manager
• EMS Administration
• ED & EMS Directors

Protocol Design
Committee

Finance &
Purchasing
Committee

Training
Committee

Implemmentation
& Review
Committee
• Project Manager
• Administratiom
• Medical Directors
• Department Directors
• Selected Staff

• Project Manager
• ED, EMS Directors,
Lab Directors
• EMS Field Training
Officers

Figure 7. Prehospital Troponin Project Committee Structural Organization

o PDC finalizes proposed protocol call design based on assumptions from
synthesis of evidence discussed in Chapter 2:
o Troponin I is the biomarker of choice in the diagnosis of NSTE-ACS
o Accelerated diagnostic pathways, utilizing high-sensitivity troponin
testing can reduce the time to diagnosis of NSTE-ACS
o The use of prehospital troponin testing in combination with an accelerated
diagnostic protocol can further reduce diagnostic time by as much as 0.29
hours in the urban setting according Ezekowitz (2015) and potentially
higher in the rural setting
o POC troponin testing in moving ambulances is not statistically different
from POC troponin

57

Establishment of protocol and training structure

Eligible
Patient
Identified

12 Lead
EKG
Obtained

+ ST
Elevation

- ST
Elevation

+ Prehospital
Troponin

- Prehospital
Troponin

+ NSTEACS
Diagnosis

+ Hospital
Troponin

- Hospital
Troponin

EIS

+ NSTEACS
Diagnosis

- NSTE-ACS
Diagnosis

EIS

Figure 8. Prehospital Troponin Testing Protocol
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o FPC meets, evaluates, selects, and obtains a POC cTnI assay platform
o TC meets and finalizes training protocol based on equipment obtained

ED Equipment
Demonstration

Power point
Presentation

Equipment
demonstration
w/proper serum
sampling

Written Testing

Psychomotor Skils
Testing

CME Granted

Figure 9 Prehospital Troponin Testing POC Training protocol
Training of EMS personnel.
o EMS Medical Director
o EMS Supervisors
o EMS Field Training Officer
o EMS Field Personnel
o Protocol Compliance Officer
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o Exact training details will be determined by the exact POC testing
platform selected and serum sampling will be based on existing EMS
protocols.
Dissemination of project implementation progress to stakeholders.
o Final Approved Protocol
o POC Testing Platform
o Training Plans
o Request for feedback
PDC & TC review feedback from stakeholders.
o Testing Protocol
o POC Testing Platform
o Training Protocol
o Appropriate adjustments made
Tabletop simulations of POC platform with EMS personnel.
o TC members perform 10 tests on POC platform with same samples tested
by receiving ED for validation
Field simulations performed in ambulances.
o TC members perform 10 tests on POC platform in moving ambulance
simulation with same samples tested by receiving ED for validation
Dissemination of simulation results to stakeholders from simulations.
o Review Prehospital Troponin Testing Protocol
o Review training records
o Review simulation results
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o Implementation plan developed
o Implementation date determined
Table 1. Prehospital Troponin Testing Protocol
PREHOSPITAL TROPONIN
TESTING PROTOCOL (PTTP)
STEP 1: Eligible Patient Selected
(Patient Population) who is > 18 years of
age with chest pain of suspected cardiac
origin with onset of symptoms < 12
hours.

STEP 2: Initial 12 Lead EKG Obtained
and send to receiving ED. If ST segment
elevation is present STOP PTTP and
proceed with STE-ACS Management

STEP 3: First troponin obtained via POC
cTnI troponin testing platform. If
troponin is + NSTE-ACS Diagnosis –
alert ED for EIS initiation

EVIDENCE
Amsterdam (2014) – Guidelines of
ACC/AHA for Management for NSTEACS:
o Risk for NSTE-ACS  > 18 y/o
o Other causes of non-NSTE-ACS
chest pain: trauma, neurological,
respiratory, gastrointestinal,
genitourinary
o Symptoms > 12 hours from onset
make troponin assays unreliable
Roffi (2015) - chest discomfort is leading
symptom that initiates the
diagnostic and therapeutic cascade
in patients with suspected ACS and
chest discomfort patients
frequently utilize emergency
medical services (EMS) for
transport to the ED
Amsterdam (2014) – Guidelines of
ACC/AHA for Management for NSTEACS:
o Obtained as soon as possible after
onset of symptoms
o ST elevation indicates STE-ACS –
alert ED & PCI Services.
Medications according to Level II
guidelines.
Amsterdam (2014) – Guidelines of
ACC/AHA for Management of NSTEACS:
o Obtain first troponin as soon as
possible after onset of symptoms
Appendix D – Study Methodology
Synthesis Table
Borna (2016) they demonstrated that cTnI
testing was a superior biomarker to
diagnose NSTE-ACS
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Table 1. Prehospital Troponin Testing Protocol
Ezokowitz (2015) use of prehospital
troponin testing reduces the time to
diagnosis and intervention
Morrow (2001) demonstrated patients with
clinically documented NSTE-ACS
derive a large clinical benefit from
the utilization of an EIS
Sorenson (2011) indicated implementation
of quantitative prehospital troponin
testing by paramedics is feasible
and effective
Venturini, 2013 - utilization of prehospital
personnel to use POC devices to
measure cTnI levels during
transport of patients to the ED may
result in earlier diagnosis of NSTEACS
STEP 4: Patient transport to receiving
Amsterdam (2014) – Guidelines of
ED and second troponin is obtained in 90
ACC/AHA for Management for
minutes to 2 hours
NSTE-ACS - Diagnostic pathway
for NSTE-ACS should be less than
2 hours from FMC
Khera (2014) - consistent benefit in the
utilization of EIS in the setting of
NSTE-ACS especially in the
setting of high-risk populations
Layfield (2014) - serial cTnI sampling
with one sample at presentation
and at least one additional sample
collected two hours later was
necessary to identify a rise or fall
in the troponin level
Wallentin (2016) - early EIS postponed
the occurrence of death or next
acute coronary event by an average
of eighteen months, and
readmission to the hospital for
ischemic heart disease by thirtyseven months, compared with a
non-invasive strategy in patients
with NSTE-ACS
Feedback results from stakeholders reviewed.
o Necessary revisions made based on feedback
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Data collection.
o Time of First Medical Contact (FMC)
o Time of First Troponin (T1)
o Time of second troponin (T2)
o Time of Disposition
o FMC to T1
o FMC to Disposition (LOS)
Baseline ED and EMS data to be obtained.
o

ED Electronic Medical Records (EMR)

o

EMS EMR/Written records and Computer-aided Dispatch (CAD) records

Table 2. Project Implementation Timeline with Process Markers
WHEN:
January 15, 2019

January 21, 2019

WHAT: Secure buy-in and willingness to
participate in project implementation
from key stakeholders. Refer to
stakeholder diagram for key stakeholders.
WHO: Project Implementation Manager
WHERE: Plainview, Texas
HOW: Presentation of EPIP slideshow
and distribution of key point pamphlets.
Obtain appropriate contact information
and schedule subsequent meetings either
in person, via Zoom or WebEx, or email.
WHAT: Revisit stakeholders and obtain
necessary agreements to participate.
WHO: Project Implementation Manager
from Texas DSHS, EMS administration,
and ED administration. These include the
EMS Medical Director, Fire Chief, ED
Medical Director and ED Director. Select
committee members for each of the four
committees.
WHERE: Plainview, Texas
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Table 2. Project Implementation Timeline with Process Markers (Continued)
HOW: In person, via Zoom, WebEx, or
email
January 28, 2019
WHAT: Finalization of protocol design
WHO: Project protocol design committee
and PIM.
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
February 1, 2019
WHAT: Disseminate results from both
Protocol Design Committee and Finance
Committee to all stakeholders and elicit
feedback. Compile feedback for next
round of committee meetings.
WHO: PIM
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
February 5, 2019
WHAT: Finalizes protocol with
consideration of equipment selected by
Finance Committee and distributes final
protocol to direct stakeholders and
requests feedback.
WHO: Protocol Design Committee and
PIM
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
February 12, 2019
WHAT: Make final decision regarding
equipment, financial acquisition plan is
made based on financial resources
selected (grant, rent, or purchase). The iSTAT POC platform offers a rental
option in addition to a purchase option.
WHO: Finance Committee & PIM
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
February 15, 2019
WHAT: Design training program in
coordination with manufacturer
guidelines. Training materials are created
and finalized. The training program will
include serum sample acquisition, POC
platform usage, POC cartridge handling
and storage, and serum sample handling.
WHO: Training Committee and PIM
WHERE: Plainview, Texas
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Table 2. Project Implementation Timeline with Process Markers (Continued)
HOW: In person, via Zoom, WebEx, or
email
February 21, 2019
WHAT; Equipment orientation and
training begins with EMS staff and
demonstration to ED staff. This training
will include testing on actual POC
platform and will include skills testing
and CEU hours for EMS staff.
WHO: PIM, Training Committee, EMS
Training Officers. PIM coordinates with
EMS Director and EMS training staff and
ED Director.
WHERE: At preselected and secured
sites in the local area.
HOW: In person with psychomotor skills
lab. Recorded for internet distribution to
staff that could not attend.
February 22, 2019
WHAT: Equipment training is completed
and table top testing initiated. Table top
testing is testing with POC platform
quantitative testing solutions in simulated
EMS scenarios. Table top results will be
disseminated to stakeholders and
feedback requested.
WHO: PIM, Training Committee,
Implementation & Review Committee,
EMS Medical Director, and EMS
Training Staff.
WHERE: Plainview, Texas
HOW: In person in the local area.
February 23, 2019
WHAT: Mach patient testing in EMS
vehicle patient simulations with
comparison to ED values on same serum
samples. Serum samples will be testing in
a moving ambulance and the same sample
will then be testing in the ED setting to
validate the accuracy of prehospital
troponin testing. These results will be
disseminated to all stakeholders and
feedback requested.
WHO: PIM, Training Committee, EMS
Training Staff, Equipment Committee,
Medical Directors, Laboratory staff, ED
& EMS Directors.
WHERE: Ambulances from the local
EMS selected for the project
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Table 2. Project Implementation Timeline with Process Markers (Continued)
implementation. Receiving ED utilized
for project.
HOW: In person
February 25, 2019
WHAT: Protocol reviewed and finalized
for implementation. Revisit with direct
and indirect stakeholders and provide
status reports and request feedback. All
testing results and feedback review and
any suggested changes implemented and
final protocol disseminated to
stakeholders and final approval obtained.
WHO: PIM, Protocol Design Committee,
Training Committee, Implementation &
Review Committee, Interested
stakeholders, Medical Directors,
Administrators and Industry Mentor.
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
February 28, 2019
WHAT: Full scale protocol initiation.
WHO: An expert group consisting of
PIM, Implementation & Review
Committee, Training Committee, EMS
Medical Director, ED Medical Director,
Project Manager, EMS Director and ED
Director.
WHERE: EMS ambulances and ED.
HOW: In person
March 5, 2019
WHAT: Process markers evaluated. First
data set compiled and reviewed.
Stakeholders notified of results and
feedback requested. Review the process
markers and make adjustments as
necessary.
WHO: PIM and all interested parties.
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
March 10, 2019
WHAT: Second data set compiled and
evaluated. Data charts updated and
variances identified and protocol
adjustments made if needed.
WHO: PIM, Implementation & Review
Committee, Industry Mentor, Medical
Directors, Administrators, and interested
stakeholders
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Table 2. Project Implementation Timeline with Process Markers (Continued)
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
March 17, 2019

March 26, 2019

WHAT: Third data set compiled and
evaluated. Data charts updated and
variances identified and protocol
adjustments made if needed.
WHO: PIM, Implementation & Review
Committee, Industry Mentor, Medical
Directors, Administrators, and interested
stakeholders
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email
WHAT: Initial implementation complete
WHO: PIM, Implementation & Review
Committee, Industry Mentor, Medical
Directors, Administrators, and interested
stakeholders
WHERE: Plainview, Texas
HOW: In person, via Zoom, WebEx, or
email

67

Figure 10. Final Prehospital Troponin Testing Protocol Project resources.
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o EMS service with ambulances and at least one Texas Department of State
Health Services certified/licensed paramedic or Nationally Registered
Emergency Medical Technician – Paramedic
o IV start equipment
o Blood sampling equipment
o POC Troponin Test Platform with storage system
o Appropriate Troponin I Cartridges
o Printer Paper for POC Platform
o Green Top Serum Blood Tubes
o Serum Blood Sampling Pipets
o Training Materials (Pamphlets)
o Training Sites
o Serum Blood Samples or manufacturer testing solutions
o EMS Vehicles for simulation testing
o Computer or tablet for data set storage, email, and presentation
o Computer Aided Dispatch System capable of documenting EMS response
variables
o EMR capable of accurately documenting patient care and times
o Printer
o Office Supplies (Paper, Ink, Legal Pads, Pens, etc.
Financial analysis for 30-day implementation.
i-STAT Analyzer Rental/month ($599X2) = $1,198
i-STAT Printer Rental/month ($125X2) = $250
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i-STAT cTnI Cartridges/25 ($629.95X2) = $1,259.90
i-STAT Rental Deposit ($7500X2) = $15,000
3 mL Plastic Pipet (200) = $8.99
BD Vacutainer Blue Citrate 2.7 mL Tubes (100) = $16.74
DB Vacutainer (100) = $33.95
Biohazard Bags (100) = $12.65
TOTAL = $17,780.23
- $15,000.00
NET

= $ 2,780.23

Evaluation of Models in PHTTP
The ACE Star Model for Knowledge Transformation and Lippitt’s Change theory
were both effective in ensuring success for this implementation. The steps of the change
theory were congruent with this type of implementation and the Star Model was
beneficial as a tool to justify changes in the current ways of thinking regarding troponin
testing, utilization of EMS in this change, and the knowledge shift necessary to create this
shift. The Star Model was particularly useful in that it organized both old and new
concepts to improve care into a collective unit and provided a framework to organize the
process. The PHTTP was a combination of older concepts (two troponin values must be
performed in the ED) and a newer concept (performing one troponin outside the ED) into
its current form (one troponin in the prehospital environment and one in the ED).
Conclusion
The PHTTP has the potential to save significant annual health care expenses with
only a limited initial investment and limited continuing expenses in relation to potential
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benefits. These benefits can be realized through the reduction in time from FMC to T1,
reduction in LOS, and reduction in time to EIS. This protocol will also reduce the impact
of MACE events in NSTE-ACS patients over its widespread implementation. These
benefits will improve patient outcomes and reduce the economic impact of patients with
NSTE-ACS diagnosis. American EDs are currently in crisis as they have become the
health care safety net, which has led to dangerous overcrowding. Projects such as this
one that aim not only at improving patient care but also at reducing ED overcrowding
through improvement in ED workflow could be pivotal in managing the ED crisis.
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Chapter 4
Project Outcomes, Impact, and Results
Completion Outcomes
The completion outcomes to be measured by the PHTTP include:
•

Reduction in mean time from FMC to T1

•

Reduction in mean LOS

•

No significant change in mean EMS scene times

Data Collection, Measurement, and Analysis
All implementation data points were recording in minute format (XX.XX
minutes). EMS times were obtained from written run reports, POC equipment and
computer-aided dispatch (CAD) equipment used by the Plainview Fire-EMS Department
for 30 days preceding implementation of the PHTTP. ED times were acquired from the
Covenant Plainview ED Meditech EMR for 30 days preceding implementation of the
PHTTP. Change in FMC to T1 = (mean pre-implementation FMC to T1 - mean post
implementation FMC to T1). Change in LOS = (mean pre-implementation LOS - mean
post implementation LOS). Change in EMS scene time = mean pre-implementation
scene time - pre-implementation scene times). Times were converted to fractional hours
by divided by 60 minutes. Percent change = (post implementation value/preimplementation value) X 100. Statistical significance was calculated using a Single
Sample t-Test with a two-tailed hypothesis and a 0.05 significance level.

Pre-implementation data.
The mean ED LOS for 30 days preceding the project implementation was 191minutes (3.18 hours) and mean FMC to T1 was 79-minutes (1.32 hours). Mean EMS
scene time for 30 days preceding implementation was 13 minutes (0.22 hours).
Project results and impact.
Table 3. Prehospital Troponin Testing Protocol - Field Data
ID

AGE

SEX

FMC

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

48
39
70
44
69
52
61
29
39
60
57
66
40
66
79
47
66
81
59
54
90
51
30
49
60

M
M
F
F
M
F
M
F
M
M
M
F
F
M
M
M
M
F
F
F
M
F
M
M
F

10:04
4:44
15:22
8:22
22:53
6:14
10:19
5:21
16:27
18:10
7:01
5:10
11:14
8:01
5:32
12:12
19:08
6:15
11:15
21:14
4:22
12:01
16:23
8:10
14:17

DEPART
ED
10:18
4:55
15:37
8:35
23:08
6:24
10:35
5:41
16:39
18:28
7:16
5:28
11:33
8:20
5:44
12:28
19:35
6:31
11:33
21:30
4:37
12:16
16:35
8:21
14:29

T1

RESULT

10:28
5:07
15:45
8:46
23:10
6:30
10:44
5:46
16:47
18:35
7:23
5:22
11:32
8:23
6:01
12:35
19:32
6:41
11:39
21:40
4:39
12:18
16:47
8:35
14:40

NEG
NEG
NEG
NEG
POS
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG

ARRIVE
ED
10:30
5:07
15:47
8:48
NA
6:31
10:44
5:48
16:50
18:52
8:04
5:37
11:33
8:21
6:09
12:31
19:36
6:36
11:39
21:48
4:50
12:20
16:50
8:33
14:44

LEGEND:
AD
ARRIVE ED
DC
DEPART ED
DISPO
F

Admission
Arrival at ED
Discharge
Depart to ED
Disposition
Female

FMC
ID
LOS
M
T1
T2
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First Medical Contact
Unique Patient Identifier
Length of Stay
Male
First Troponin Value
Second Troponin Value

Table 4. Prehospital Troponin Testing Protocol - ED Data
T2

RESULT

DISPO

LOS

DIFF

11:55
6:32
17:17
10:00
NA
7:40
12:01
6:05
18:09
18:43

NEG
NEG
NEG
NEG
NA
NEG
NEG
NEG
NEG
NEG

13:01
7:48
17:51
11:01
NA
8:44
13:19
8:33
19:10
21:21

DC
DC
AD
DC
NA
DC
AD
DC
DC
AD

151.00
161.00
124.00
133.00
NA
133.00
155.00
165.00
140.00
149.00

40.00
30.00
67.00
58.00
NA
58.00
36.00
26.00
51.00
42.00

8:45
6:59
12:59
10:02
8:00
14:07
21:17
8:30
13:28
23:25
6:35
14:17
18:30
10:24
16:20

NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG

10:34
8:52
14:12
10:47
9:12
14:25
22:01
9:05
14:20
23:52
7:10
14:54
19:12
11:33
17:12

DC
DC
DC
DC
T
DC
AD
AD
DC
DC
AD
DC
DC
DC
DC

150.00
195.00
159.00
146.00
183.00
114.00
145.00
149.00
161.00
124.00
140.00
154.00
142.00
180.00
148.00

41.00
-4.00
32.00
45.00
8.00
77.00
46.00
42.00
30.00
67.00
51.00
37.00
49.00
11.00
43.00

LOS 150.04

AVERAGE LOS CHANGE

40.96

LEGEND:
AD
ARRIVE ED
DC
DEPART ED
DISPO
F

Admission
Arrival at ED
Discharge
Depart to ED
Disposition
Female

FMC
ID
LOS
M
T1
T2
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First Medical Contact
Unique Patient Identifier
Length of Stay
Male
First Troponin Value
Second Troponin Value

Table 5. Prehospital Troponin Testing Project Age Distribution
ID

AGE

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

48
39
70
44
69
52
61
29
39
60
57
66
40
66
79
47
66
81
59
54
90
51
30
49
60

AVERAGE

56.24
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Table 6. Prehospital Troponin Testing Project Gender Distribution
MALE
FEMALE

14
11

56%
44%

Table 7. Prehospital Troponin Testing Project FMC to First Troponin Average
ID

FMC

T1

DIFF

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

10:04
4:44
15:22
8:22
22:53
6:14
10:19
5:21
16:27
18:10
7:01
5:10
11:14
8:01
5:32
12:12
19:08
6:15
11:15
21:14
4:22
12:01
16:23
8:10
14:17

10:28
5:07
15:45
8:46
23:10
6:30
10:44
5:46
16:47
18:35
7:23
5:22
11:32
8:23
6:01
12:35
19:32
6:41
11:39
21:40
4:39
12:18
16:47
8:35
14:40

0:24
0:23
0:23
0:24
0:17
0:16
0:25
0:25
0:20
0:25
0:22
0:12
0:18
0:22
0:29
0:23
0:24
0:26
0:24
0:26
0:17
0:17
0:24
0:25
0:23

AVERAGE

0:22
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Table 8. Prehospital Troponin Testing Project FMC to Arrival at Emergency Department
ID

FMC

ARRIVE ED

DIFF

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

10:04
4:44
15:22
8:22
22:53
6:14
10:19
5:21
16:27
18:10
7:01
5:10
11:14
8:01
5:32
12:12
19:08
6:15
11:15
21:14
4:22
12:01
16:23
8:10
14:17

10:30
5:07
15:47
8:48
NA
6:31
10:44
5:48
16:50
18:52
8:04
5:37
11:33
8:21
6:09
12:31
19:36
6:36
11:39
21:48
4:50
12:20
16:50
8:33
14:44

0:26
0:23
0:25
0:26
NA
0:17
0:25
0:27
0:23
0:42
1:03
0:27
0:19
0:20
0:37
0:19
0:28
0:21
0:24
0:34
0:28
0:19
0:27
0:23
0:27

AVERAGE
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0:27

Table 9. Prehospital Troponin Testing Project Troponin 1 to Troponin 2 Average
ID

T1

T2

DIFF

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

10:28
5:07
15:45
8:46
23:10
6:30
10:44
5:46
16:47
18:35
7:23
5:22
11:32
8:23
6:01
12:35
19:32
6:41
11:39
21:40
4:39
12:18
16:47
8:35
14:40

11:55
6:32
17:17
10:00
NA
7:40
12:01
6:05
18:09
18:43
8:45
6:59
12:59
10:02
8:00
14:07
21:17
8:30
13:28
23:18
6:35
14:17
18:30
10:24
16:20

1:27
1:25
1:32
1:14
NA
1:10
1:17
0:19
1:22
0:08
1:22
1:37
1:27
1:39
1:59
1:32
1:45
1:49
1:49
1:38
1:56
1:59
1:43
1:49
1:40

AVERAGE

1:29
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Table 10. Prehospital Troponin Testing Project Troponin 2 to Disposition Average
ID

T2

DISPO

DIFF

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

11:55
6:32
17:17
10:00
NA
7:40
12:01
6:05
18:09
18:43
8:45
6:59
12:59
10:02
8:00
14:07
21:17
8:30
13:28
23:25
6:35
14:17
18:30
10:24
16:20

13:01
7:48
17:51
11:01
NA
8:44
13:19
8:33
19:10
21:21
10:34
8:52
14:12
10:47
9:12
14:25
22:01
9:05
14:20
23:52
7:10
14:54
19:12
11:33
17:12

1:06
1:16
0:34
1:01
NA
1:04
1:18
2:28
1:01
2:38
1:49
1:53
1:13
0:45
1:12
0:18
0:44
0:35
0:52
0:27
0:35
0:37
0:42
1:09
0:52

AVERAGE

1:05
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Table 11. Prehospital Troponin Testing Project EMS Scene Time
ID

FMC

DEPART

DIFF

001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
019
020
021
022
023
024
025

10:04
4:44
15:22
8:22
22:53
6:14
NA
5:21
16:27
18:10
7:01
5:10
11:14
8:01
5:32
12:12
19:08
6:15
11:15
21:14
4:22
12:01
16:23
8:10
14:17

10:18
4:55
15:37
8:35
23:08
6:24
10:35
5:41
16:39
18:28
7:16
5:28
11:33
8:20
5:44
12:28
19:35
6:31
11:33
21:30
4:37
12:16
16:35
8:21
14:29

0:14
0:11
0:15
0:13
0:15
0:10
NA
0:20
0:12
0:18
0:15
0:18
0:19
0:19
0:12
0:16
0:27
0:16
0:18
0:16
0:15
0:15
0:12
0:11
0:12

AVERAGE

0:15

80

There were 25 eligible patients included in the 30 day preliminary PHTTP data
set. One patient was excluded for a positive T1 and ST segment elevation on ECG and a
subsequent diagnosis of STEMI. The average ago of the study participants was 56.24
years and 56% male and 44% female. The PHTTP preliminary data demonstrated a
reduction in the time of mean FMC to T1 from 79 minutes (1.32 hours) to 22 minutes
(0.37 hours) and mean FMC to disposition of patients from 191.00 minutes (3.18 hour) to
150.04 minutes (2.50 hours). Mean FMC to T1 was reduced by 47.00 minutes (0.78
hours) and LOS was reduced by 40.96 minutes (0.67 hours). This equated to a 21.19%
reduction in mean ED LOS of this subset of patients in the Covenant Plainview ED. The
mean EMS scene time increased from 14 minutes (0.23 hours) to 15 minutes (0.25
hours). During the implementation period the mean time to return of T1 was reduced to
10 minutes (0.17 hours) through POC testing which equated to a reduction of 57 minutes
(0.95 hours) or a 14.9% improvement. Mean return time of T2 was not significantly
different at 78 minutes (1.32 hours), compared to 79 minutes (1.32 hours) as it was
processed in the Covenant Plainview Lab with via the same instrumentation and protocol.
The mean LOS was reduced from 191 minutes (3.18 hours) to 150.04-minutes (2.5 hours)
which equated to a reduction of 40.96-minutes (0.67 hours) or a 21.19% improvement.
Analysis.
The sample data was analyzed using a Single Sample t-Test with a two-tailed
hypothesis and a 0.05 significance level. This test was used to determine if the post
implementation values were statistically different from the pre-implementation values.
The time from mean FMC to T1 t-value = -10.665324 at p = < 0.00001 and LOS t-value
= -72.249049 at p = < 0.00001 which are both statistically significant at p = 0.05. Mean
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EMS scene time t-value = 1.790249 at p = 0.086588 which is not statistically significant
at p = 0.05.
Conclusion
The preliminary results of the PHTTP corresponded with the postulated outcome
measures by reducing the mean time to final disposition and mean LOS of chest pain
patients that arrived at the ED via EMS. These measures were attained through the
introduction of a prehospital troponin value that reduced the time from mean FMC to T1.
The reduction in time from mean FMC to T1 concomitantly reduced the mean LOS
without a significant increase in mean EMS scene time of chest pain patients transported
by Plainview Fire-EMS to Covenant Plainview ED.
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Chapter 5
Project Sustainability, Discussion, Conclusions, and Dissemination Recommendations
Discussion of Results and Impact
The PHTTP preliminary data demonstrated a reduction in the time from mean
FMC to T1 and mean FMC to disposition of patients who were transported to the
Covenant Plainview ED via Plainview Fire-EMS from 191 minutes (3.18 hour) to 150.04
minutes (2.50 hours). This reduced the mean LOS by 40.96 minutes (0.67 hours). This
equated to a 21.19% reduction in mean ED LOS for this subset of patients in the
Covenant Plainview ED. This reduction in time to T1 had the following immediate
impacts: 1) reduced the time from mean FMC to T2, 2) reduced the time from mean FMC
to T2, and 3) reduced the time from mean FMC to final disposition which could include
discharge, admission, or transfer. Its intermediate impacts include the following: 1)
reduction in time to EIS and 2) reduction in ED overcrowding and improved ED
workflow. Long-term impacts potentially include the following: 1) improved patient
outcomes through reduction in 90-day MACE events, 2) improved ED patient
satisfaction, 3) improved Fire-EMS and ED collaboration and satisfaction, and 4) reduced
institutional costs from subsequent hospitalization related to 90-day MACE. The
potential long-term impacts require ongoing implementation of the PHTTP to validate.
Project Sustainability Plans and Implementation
Sustainability occurs through standardization and conservation of new practices
over time requiring stakeholders, including management and staff to fundamentally alter

their thinking and attitudes towards a process innovation. Sustainable change in health
care must be dynamic and adaptive to meet contextual needs and maintain desirable
patient outcomes (Scheirer & Dearing, 2011). Refer to Figure 9 for PHTTP
sustainability plan.
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Figure 11. Prehospital Troponin Testing Project Sustainability Plan
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Dissemination, feedback, and adjustment phases.
The initial step of ensuring the sustainability of the PHTTP is to maintain the
engagement and investment of the key stakeholders, as well as identifying additional
stakeholders and potential barriers to ongoing sustainability. The dissemination of the
preliminary results of the PHTTP to stakeholders will be done through a combination of
media formats including print, electronic, and in-person presentations via presentation
platforms such as Microsoft PowerPoint. This media will be distributed to the
administration of both the Covenant Plainview Hospital, the Plainview Fire-EMS
Department, and the City of Plainview. An article will be written for publication in the
Plainview Daily Herald detailing the PHTTP and the involvement of both the fire
department and the hospital ED. This process of preliminary result and project
dissemination will identify any potential stakeholder, financial, political, or organizationrelated barriers and aid in developing potential strategies necessary to overcome these
barriers and facilitate ongoing implementation of the PHTTP.
Potential barrier and their solutions are as follows:
•

Stakeholder: All major stakeholders involved in the PHTTP were initially vested
and discussions of their preliminary results demonstrated continued investment.
The official dissemination of the preliminary data in additional to the concurrent
data collection will assist in continuing their involvement and participation.

•

Financial: Ongoing expense of sustaining the PHTTP. There is an initial durable
and ongoing consumable equipment cost, but it can be offset over the long-term
as troponin testing is a reimbursable intervention by major insurance providers,
Medicare, and Medicaid (Kip, 2017). The Texas Department of State Health
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Services has many grant services available for licensed EMS providers in the
State of Texas and the preliminary data from PHTTP will be utilized with grant
writing (Texas Department of State Health Services, 2019). In conjunction with
the Plainview Fire-EMS, grant applications will be made to U.S. and Texas
Department of State Health Services (DHS) and Department of Homeland
Security Federal Emergency Management Agency (FEMA) to obtain permanent
durable POC and consumable equipment to fund the ongoing training and
education. Additionally, a billing policy will be implemented to ensure
appropriate reimbursement to the Plainview Fire-EMS for POC troponin testing to
sustain ongoing consumable equipment procurement. These steps will support
the continuation of the PHTTP until adequate reimbursement has been obtained
and the PHTTP is self-sustained.
•

Political: There was a concern regarding the increased liability of the City of
Plainview using the fire department to perform tests previously completed by the
hospital laboratory. The city attorney was provided the literature that
demonstrated no increase in liability from the utilization of POC testing and that
POC testing is the standard of care in the management of chest pain patients
(Juliano, 2017).

•

Organizational: Plainview Clinical Laboratory resisted the continuation of
PHTTP. The Plainview Clinical Laboratory demonstrated initial resistance to
troponin values being obtained outside of their facility due to potential lack of
reliability, loss of revenue, and lack of Clinical Laboratory Improvement
Amendments (CLIA) certification. These issues were addressed via in-person
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meetings and the provision of literature regarding the reliability of out-oflaboratory troponin results (Juliano, 2017), demonstration of troponin testing
platform, cost benefit analysis regarding reagents, cartridges, staff, and equipment
maintenance cost regarding potential billing amounts, and documentation of POC
troponin testing being a CLIA-waived test (Center’s for Medicare and Medicaid
Services, 2018).
Plan for initial dissemination of preliminary data.
This plan includes the following: 1) In-person or round table meeting with key
stakeholders to disseminate the preliminary results of the PHTTP and address any
potential barriers to continued implementation, 2) presentation to city council and
publication of preliminary results and involvement of important stakeholders in city
newspaper and fire department, hospital, and city website, 3) meetings with financial
officers of City of Plainview and Covenant Plainview Hospital as well as meeting with
Texas Department of State Health Services EMS Grants Division, 4) community
presentation to interested individuals, and 5) publication in selected journals.
Dissemination.
•

Oral presentation with PowerPoint Slides to DNP cohort, UT Tyler DNP
Faculty, Covenant Plainview ED staff and administration, Plainview FireEMS and Plainview City Council

•

Newspaper articles presentation

•

Poster presentation to stakeholders

•

Community meetings

•

Media announcements: Radio/Television
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•

Presentation at Texas EMS conference

•

Article publications in scholarly journals:
•

Academic Emergency Medicine

•

Journal of Advanced Emergency Nursing

•

Journal of the American College of Cardiology

•

Journal of Prehospital Emergency Care

•

Journal of Emergency Medical Services

Funding phase.
Sustainability of the PHTTP requires ongoing funding from the host
organizations. This funding can be secured from internal as well as external sources.
Internal sources of funding include inclusion in departmental and organizational
budgetary planning meetings with the Chief Financial Officers of both host organizations
and meetings with billing agencies to procure appropriate reimbursement for POC testing
as outlined by CMS. External sources of funding include donations from community
partners identified through dissemination of preliminary results at town hall meetings and
media, private funding organizations such as Abbott Point-of-Care, and grant applications
that will be made to the United States and Texas Department of State Health Services
(DHS), and Department of Homeland Security Federal Emergency Management Agency
(FEMA).
Dynamic re-evaluation phase.
As the PHTTP continues within the host organizations a continual evaluation and
of project outcomes and dynamic adjustment to problems or new barriers is necessary.
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Sustainability cannot be maintained within a static situation and continual dynamic
change based on outcomes measures and stakeholder feedback must occur.
Organizational readiness phase.
The readiness of the host organizations for sustained change must be assessed
prior to full project integration to assess organizational strengths and weaknesses. The
Organizational Readiness for Change Assessment (ORCA) tool will be utilized to reevaluate the readiness of the host organizations prior to full and sustained implementation
following the initial implementation phase. The ORCA tool is utilized to identify and
monitor the organizational strengths and weaknesses to support a sustain implementation
of evidence-based practices (Helfrich, 2009). Any weaknesses identified will be
addressed with organizational leadership and adaptations made to facilitate complete
project integration and sustainability.
Project integration phase.
PHTTP is integrated in the budget, facility protocols, and training practices at
both host organizations as a Standard Operating Procedure (SOP) through Project
Integration Management (PIM). PIM is the process of integrating new processes into a
complex, fully functional system to minimize system interruption and create sustainable
system change (Project Management Institute, 2017).
The utilization of the PHTTP sustainability plan will create a sustainable change
within both the Plainview Fire-EMS Department and the Covenant Plainview ED. This
sustainable change will improve inter-professional collaboration between these
organizations, improve outcomes of chest pain patients, improve ED workflow, and
reduce ED overcrowding.
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Implications of PHTTP Results
The preliminary results of the PHTTP have implications in the ongoing
management of chest pain patients transported to the Covenant Plainview ED via
Plainview Fire-EMS. Further, improved inter-professional collaboration between the
prehospital staff and ED staff can improve the patient outcomes and facilitate patient
transition from the prehospital to the hospital setting (Reeves, 2017). The PHTTP
demonstrated that prehospital personnel are important in the patient progression through
emergent evaluation through the inclusion and reliance upon troponin values obtained
outside the ED as well as the hospital clinical laboratory (Venturini, 2013). The PHTTP
preliminary results demonstrated that a prehospital troponin value is reliable and effective
in decreasing the throughput time of chest pain patients in the ED which would
concomitantly decrease the time to disposition and utilization of EIS if it is required. The
utilization of prehospital personnel to use POC devices to measure troponin levels during
transport of patients to the ED may result in earlier diagnosis of ACS (Venturini, 2013).
Moreover, EIS leads to a statistically significant decrease in mortality and refractory
ischemia (Li, 2017). Additionally, the PHTTP will reduce healthcare costs by using
interventions earlier in the patient treatment algorithm and reduce readmissions and
mitigate adverse outcomes. In fact, readmission costs are $14,300 following discharge
from an NSTE-ACS events (Patel, 2018). With early intervention, the re-hospitalization
rate was decreased by 9% (Meadows, 2012). The PHTTP can reduce re-hospitalizations
by 9% by reducing the time to interventional strategies and readmission costs of
$14,300/event. Finally, the PHTTP preliminary results improved ED workflow and
reduced ED overcrowding by decreasing the LOS of chest pain patients that arrive by
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EMS. EDs in the US are in crisis from overcrowding as it has become the safety net for
health care (Freibott, 2017). Therefore, this PHTTP has the potential to create
sustainable change within the local healthcare environment and if implemented on a
larger scale will have positive ramifications in the larger health care environment.
Key Lessons Learned from Implementation Process
Many lessons were learned during the design, recruitment, and implementation of
the PHTTP: 1) resistance to inter-professional collaboration, 2) financial investment of
the health care components, and 3) investment in innovation. Collaboration between
EMS systems and hospital EDs can often be turbulent and strained and the PHTTP
required extensive cooperation between these two systems. Additionally, dealing with
the administrative structure of one component of the health care system can often be
taxing, but dealing with the administration of two components concurrently was the real
challenge. The investment of financial capital in the current strained health care system
was a major hurdle to implementation of the PHTTP. The exploration of grants and
organizational donations would be beneficial for the implementation of future projects of
this type that involve more than one health care component. Even in the contemporary
evidence-based emergency health care system, barriers still exist against the
implementation of innovative approaches to established treatment algorithms and many
systems are uncomfortable in straying from the established norms. This variation from
the established norms represented a challenge through the process of this project and
required greater adaptation than what was previously anticipated.
Recommendations
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The preliminary results of the PHTTP demonstrated a reduction in the time to
final disposition of chest pain patients suspected of NSTE-ACS that present to the
Covenant Plainview ED via Plainview Fire-EMS. The ongoing implementation
demonstrated a 40.96 minute (0.67 hour) reduction in time to final disposition which
could create sustainable change is patient outcomes and ED workflow. Future
recommendations for this project are as follows: 1) the current PHTTP should be
continued in the host organizations and additional data obtained, 2) the PHTTP
Sustainability Plan should be enacted in the host organizations while the additional data
is obtained, and 3) once adequate sustainability is obtained within the host organizations,
considerations can be made for project implementation in other organizations.
.
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Appendix A. All-cause Mortality
Mortality Post Discharge

NSTE-ACS

AMI

30 day

2.6%

7.99%

90 day

12.6%

6.1%

180 day

18.3%

10.2%

1 year

23.5%

11.5%

2 year

33.2%

16.4%

Appendix B. Prehospital Troponin Evaluation Table Template
Used with permission, © 2007 Fineout-Overholt
Citation:
author(s)
, date of
publicati
on& title

Purpose
of Study

Conc
eptua
l
Fram
ewor
k

Design/
Method

Cantor,
W., et al.
Em
Medicine
2005;
16(1), 19.

Evaluate
PCI
impact

None

RCT
OPUS
TIMI-16
Trial

Sample/Settin
g

N= 10,288 in
10 months
Setting:
hospitalized
patient in 29
countries

Major
Variables
Studied
and
Their
Definition
s
IV = EIS
DV1 = OT
DV2 = PCI

Measurement
of Major
Variables

Event rates
mortality at 10
months in OT
& PCI groups

Data
Analysis

Percent
Hazard
Ratios
Pearson test
– EIS &
OT/PCI

Attrition:
1855 excluded
due to
previous PCI

Study Findings

PCI is associated
with lower MACE
MACE st 10
months was: 1.3%
(low risk), 2.2%
(intermediate
risk), & 11.4%
(high risk)

PCI with
&
without
thrombol
ytics
reduces
MACE

None

RCT
STEMI
&
NSTEM
I
randomi
zed
equally
into 1 of
4
groups:
-BA+T
-BA-T
-SC+T
-CS-T

N = 2082 over
1 year
Setting: 76
medical
centers in 9
countries
Attrition: 36
lost to 15 year
follow-up

Limitations:
- Bias: decision to utilize EIS was at the
discretion of the treating physician
- some non-fatal outcomes Re-infarction,
stroke) may have occurred before EIS
Strengths:
-large sample (8286 after exclusions)
-identified that EIS effect varies with risk
stratification
Conclusion:
-EIS  MACE in high-risk and little
effect in low-risk

147 had
STEMI & PCI
before
randomization

Cox, D.,
et al. Am
J Card.
2006;
149(2):
275-283

Appraisal of Worth to Practice
Strength of the Evidence (i.e., level of
evidence + quality [study strengths and
weaknesses])
RECOMMENDATIONS

IV = PRS
DV1 =
BA+T
DV2 =
BA-T
DV3 =
CS+T
DV4 = CST

15 year
mortality rate
was measured
for all
intervention
groups based
on occurrence
of MACE

Percent

PCI improves
MACE versus OT

ITT
Chi-square
test for 4way
comparison
of groups
Survival
technique
and log
rank for
MACE

NSTEMI had
delayed arrival to
hospital (2.4
hours) versus
STEMI (1.8 hours)
1 year NSTEMI
MACE of 24%
versus STEMI
MACE of 16.6%

Feasibility:
-EIS is feasible to implement in high-risk
patients
-Benefits outweighs risk in high risk
patients
Limitations:
- small sample size for medication
evaluation
- retrospective analysis was not included
in original study design
Strengths:
-29 center trial
Conclusion:
-PCI strategies with & without
thrombolytics are effective in reducing
MACE
-delays in intervention lead to > MACE
for NSTEMI
Feasibility:
-reasonable to implement into ED practice

100

-benefits of MACE outweighs risk of
both PCI & thrombolytics
Ezekowit
z, J., et al.
JAHA,
2015;
4(12): 111

Than, M.,
et al,
JAMA
2013;
4(12): 111

PTT
accelerat
es TTD

Utilize
ADP
without
increasin
g MACE

None

RCT
PROAC
T-4 was
a
prospecti
ve,
openlabel,
blindedendpoint
(PROBE
).
Patients
were
randomi
zed in
the
prehospi
tal
setting
1:1 into
POCT or
UC
groups.

None

RCT
Randomi
zed 1:1
to APD
and UC

N = 601 in 19
months
UC=296
POCT=305
Setting: 25
ambulances in
Edmonton,
Alberta,
Canada

IV = PTT
DV1 =
POCT
DV2 =
TTD

+POCT > 0.03
ng/mL
Prehospital
+POCT > 0.01
ng/mL
Hospital
TTD = FMC to
FD measured
in hours

Attrition:
UC=2 –
withdrew
consent

ITT
Analysis

0.29 reduction in
TTD

Per
Protocol
Analysis

POCT = 38
minutes
UC = 139 minutes

2 sided
statistical
tests with
5% level of
significance

POCT TTD = 8.8
hrs (P=0.069;
Padjusted=0.074)

Weakness: 18% device failure with no
POCT results and patients, EMS personnel
and physicians treating the patient were
aware of the allocated arm

UC TTD = 9.0 hrs
(P=0.05;
Padjusted=0.059)

Conclusion: POCT prehospital troponin
testing resulted in 0.29 hour reduction in
time to TTD

Sensitivity of
POCT=44%,
specificity=96%,
positive predictive
value=73.3%, and
negative predictive
value=87.2%

Feasibility: this intervention is feasible to
implement into practice and has potential
for even greater positive results in longer
transport scenarios. Risk to patients is
minimal and benefit outweighs risk.

ADP doubled the
proportion of
patient with early
discharge

Limitations:
-single center trial  generalizability &
limited sample size
-cannot exclude small differences in risk
of MACE

POCT=57 –
55 no POCT
result & 2
withdrew
consent

N = 544 in 19
months

IV1 = ADP
IV2 = SCP

hs-cTn < 0.03
ng/mL

ADP=271
UC=273

IV1 = hscTn
IV2 = SD
IV3 =
MACE

SD < 2 hours

ITT
Chi-square

Setting:
Christchurch
Hospital ED
in
Christchurch,
New Zealand

Odds ratio
MACE
standard
classification

Attrition:
UC-1
ADP=1
withdrew
consent

Percentage

19.3% of ADP
patients
discharged by 6
hours
11% of UC
patients
discharged in 6
hours
52 of 270 patients
in the
experimental
group were

101

Strength: in a less-advanced EMS
systems, or greater distances or durations
of EMS transport, there may be an even
greater magnitude of the effect than
observed in this study

Strengths:
-safety of ADP was demonstrated in 1975
patients
Conclusion:
-Trial demonstrated that the experimental
pathway is an effective and practical
strategy to improve early discharge rates
for some patients with chest pain.

Wallentin
, L., et al.
Lancet
2016;
388(1005
4:19031911

EIS
reduces
MACE

None

RCT
Prospect
ive,
randomi
zed,
open and
doubleblind,
placebocontrolle
d study
with
parallel
groups

N = 2457 in
22 months
Setting: 58
Scandinavian
Hospitals in
Sweden,
Denmark, &
Norway

IV = EIS
DV1 = PCI
DV2 =
MACE

PCI – met
criteria or did
not meet
criteria for
cardiac
catherization;
upper limit of
normal

Mean Gain
Analysis
Regression
analysis
Odds ratio
HosemerLemeshow
Test

Attrition: 36 –
death & loss
to follow-up
for unknown
reason

successfully
discharged within
6 hours compared
with 30 of 272
patients in the
control group
(19.3% vs 11.0%;
odds ratio, 1.92;
95% CI, 1.183.13; P = .008)

Feasibility:

PCI reduced
MACE by a mean
of 549 days at 2
years

Limitations:
-bias towards selection of medium to high
risk patients limiting applicability to low
risk.
-confined to Scandinavian patients with
limited prior revascularization
-only risk factors present on admission
were included – excluding factors that
developed during hospitalization

PCI postponed
MACE by average
of 18 months and
readmission by 37
months compared
to UC
PCI postponed
MACE by 1128
days (95% CI 8301366)

Patients
randomi
zed to
EIS or
non-EIS

More than 5
factors for
invasive strategy
reduced mortality
from 15.4% (20 of
130) to 5.2% (7 of
134) (risk ratio
(RR) 0.34, 95%
confidence
interval (CI) 0.15
to 0.78, p = 0.006)
Death/MI was also
reduced in patients
with 3–4 factors
from 15.7% (80 of
511) to 10.8% (58
of 538) (RR 0.69,

102

- ADP is feasible to facilitate early
discharge
-Benefits of utilizing ADP outweigh
calculated risks of MACE in chest pain
patients

Strengths:
-15 year follow-up
Conclusion:
-PCI reduced occurrence of MACE events
over 15 years
Feasibility:
-feasible to implement protocol to
accelerate time to EIS
-benefits of EIS( MACE) outweigh risks
(cardiac arrhythmias, bleeding, vessel
perforation)

95% CI 0.50 to
0.94, p = 0.02)

Cullen,
L., et al.
JACC,
Lancet
2013;
62(14):
12421249

Meek, R.,
et al. Em
Med Aus.
2016;
28(3):
279-286

Stengaard
, C., et al.
ACC,
2013;112

Validate
POCT

None

Prospect
ive
Cohort
2
cohorts:
-ADAPT
-APACE

Evaluate
ADP in
reducing
MACE
and ED
discharg
e

Evaluate
POCT in
identifyi
ng ACS

None

Prospect
ive
Cohort

N = 2885
Setting: 2
urban ED in
Brisbane,
Australia &
Christchurch,
New Zealand
Attrition:
-ADAPT:
TIMI
incomplete or
no stored
serum (341)
-APACE:
CP not ACS
of hs-cTnT
above cutoff(46); no
stored
serum(655; no
ECG(6)
N = 1547 in
54 days
Setting: 3
Montash
Health ED in
Clayton,
Victoria,
Australia &
Dandenong,
Victoria,
Australia

None

Observat
ional
Prospect

Attrition:
No follow-up
= 114
N = 985 in 19
months

IV = hscTn

MACE = any

Chi-square
analysis

TIMI < 1
DV1 =
MACE
DV2 =
TIMI

McNemar
analysis

ADP protocol
reduced 30 day
MACE by 40%
ADAPT = 15.1%
of MACE st 30
days
APACE = 17.1%
MACE at 30 days

Limitations:
-applicability of risk limited to CP patient
and excludes atypical presentations
-most were Caucasian limiting
generalizability
Conclusion: An early-discharge strategy
using an hs-TnI assay and TIMI score < 1
is safe and has the potential to decrease
the observation periods and admissions for
approximately 40% of patients with
suspected ACS
Feasibility:
-applicable to integration into practice in
the ED to reduce TTD
-Benefits of reducing TDD has limited
risk of MACE

IV = ADP
DV =
MACED

MACED =
successful
discharge

Percentage

ADP supports safe
early discharge
MACED =
(0.09%, 95% CI
0.002–0.5)
UC = (0.3%, 95%
CI 0.08–0.8)

Limitations:
-subjective physician selection of eligible
patients
Conclusions:
- The ADP supports safe, early discharge
of low-risk chest pain patients from the
ED.
Feasibility:
- the use of and ADP is a safe method of
ED discharge of chest pain patients
- ADP demonstrated limited risk of
MACE

IV =
POCT
protocol

POCT > 50
ng/L

Percentage
Chi-square
test

103

Prehospital
quantitative POCT
was statistically
successful

Limitations:
-inclusion in the study at the discretion of
the paramedics creating potential selection
bias

(9): 13611366

and
reducing
MACE

ive
Cohort
Patients
with CP
< 70
minutes
in
duration

Venturini,
J., et al.
Prehosp
Em Care,
2013; 17:
89-91

Validate
POCT in
ambulan
ce versus
EDT

None

Observat
ional
Cohort
EMS
Cohort
Hospital
Cohort

Setting:
ambulances in
Central
Denmark

DV =
+POCT

KurskalWallis Test
1-way
sample ttest

Attrition:
-12 lost to
follow-up

2proportion
Z-test

N= 42 in 60
days
Setting:
Loyola
University
Hospital &
EMS in
Maywood,
Illinois

IV = PTT
DV1 =
POCT
DV2 =
EDT

POCT in
ng/mL

Intra-class
correlation

EDT in ng/mL

Diagnostic
accuracy of POCT
values was 0.67
+prehospital
POCT troponin =
MACE of 23%/yr
-prehospital POCT
MACE = 5%/yr

POCT in moving
ambulance
provided accurate
results
coefficient 0.997;
95% confidence
interval 0.994 to
0.998; p < 0.005

Attrition: 3 –
1 cartridge
error & 2
interfering
substances

Darling,
C., et al.
Clin Epi.
2013; 5:
229-236

Evaluate
MACE
after
ACS

None

Descripti
ve Study
Reviewe
d
medical
records
of
residents
of
Worcest
er, MA,
USA
metropol
itan area
hospitali
zed at
eleven

N = 3762 in
2001, 2003,
2007, & 2007

IV = ACS

Percentages

DV =
MACE

Setting: Data
from
Worcester
Heart Attack
Study
(WHAS) in
Massachusetts

Post discharge
MACE was higher
for NSTEMI than
STEMI
NSTEMI MACE:
-90 days=12.6%
-1 years=23.5%
-2 years=33.2%
STEMI MACE:
-90 days=6.1%
-1 year=11.5%
-2 years=16.4%

Attrition:
-NA

STEMI were
significantly more
likely to have

104

-baseline data retrieved from incomplete
databases
Strengths:
-demonstrated adequate correlation of
prehospital POCT results
Conclusions:
-large-scale quantitative prehospital POCcTnI testing by paramedics is feasible
Feasibility:
-is applicable to utilization of prehospital
troponin testing protocol
Limitations:
-small sample size
-devices were not subject to normal
adverse conditions
-device had 7.2% failure rate
Strengths:
-results were highly correlated
Conclusions:
- When used in a moving ambulance, the
i-STAT point- of-care device reliably
provided accurate results of troponin
assays when compared with the results of
those performed in the ED
Feasibility:
-applicable to the practice of prehospital
troponin testing
Limitations:
-primary Caucasian limits generalizability
-non-randomized
Strengths:
-large sample size N=3762
Conclusions:
- patients with STEMI experienced a
better post-discharge prognosis than those
with NSTEMI
Feasibility:
-provides validity to the assertion that
NSTEMI patients are at higher risk for
MACE and an intervention is needed to
mitigate this risk

central
Massach
usetts
medical
centers
for acute
myocard
ial
infarctio
n (AMI)
during
2001,
2003,
2005,
and
2007

survived at 3
months (OR 1.38;
95% CI 1.01–
1.87), 1 year (OR
1.38; 95% CI
1.09–1.74), and 2
years (OR 1.53;
95% CI 1.23–
1.89) (all P-values
,0.05)
NSTEMI were
significantly more
likely to have died
during the years
under study than
patients with
STEMI (adjusted
HR = 1.28; 95%
CI 1.14–1.44) (Pvalue ,0.05)

ACS-Acute Coronary Syndrome; ADAPR-Accelerated Diagnostic Protocol to Assess Patients with Chest pain with Troponin; ADP-Accelerated Diagnostic Protocol; APACEAdvantageous Predictors of Acute Coronary Syndromes Evaluation; BA+T-Balloon Angioplasty w/Thrombolytics; BA-T-Balloon Angioplasty w/o Thrombolytics; CS+T-Cardiac
Stent w/Thrombolytics; CS-T-Balloon Angioplasty w/o Thrombolytics; EDT-Emergency Department Troponin; EIS-Early Invasive Strategy; EMS-Emergency Medical Services;
FMC-First Medical Contact; FD-Final Diagnosis; hs-cTn-high-sensitivity Troponin; ITT-Intention to Treat; MACE-Major Adverse Cardiac Events; MACED-MACE with ED
Discharge; NSTEMI-non-ST segment Elevation Myocardial Infarction; OT-Oral Thrombolytics; PCI-Percutaneous Cardiac Intervention; POCT-Point-of-Care Troponin; PRSPrehospital Stratification; PTT-Prehospital Troponin Testing; RPD-Rapid Diagnostic Pathway; SD-Successful Discharge; STEMI-ST-segment Elevation Myocardial Infarction; TIMIThrombolysis in Myocardial Infarction; TTD-Time to Final Diagnosis; UC-Usual Care;

105

Appendix C. Search Results Synthesis Table
DATABASE

CINAHL

KEYWORD

COCHRAN

TITLE

SUBJECT

COMBO:

PUBMED

KEYWORD

TI/AB/KW

SEARCH TERM

MESH

MESH MAJOR

TITLE/

TERMS

TOPIC

ABSTRACT

TITLE

MESH
TITLE

Acute Coronary Syndrome

3956

2292

1291

4455

3128

22646

25079

14051

6207

11609

ACS

1859

0

162

2542

2

25079

2006

12319

976

717

non-ST segment elevation myocardial
infarction

339

0

0

947

456

2006

1744

990

347

1454

NSTEMI

195

0

23

289

0

1744

1457

1382

111

163

non-ST segment acute coronary syndrome

315

0

66

727

321

1457

695

465

244

1679

NSTE-ACS

98

0

4

245

0

695

2205

695

45

0

Troponin

2377

1874

832

2638

2064

14627

14627

12523

5023

10672

High Sensitivity Troponin

327

0

130

418

21

2205

2205

493

250

1817

Prehospital Troponin

118

35

0

190

146

431

431

16

13

342

Point of Care Troponin

15

7

0

14

11

48

48

44

13

31

Early Invasive Strategies

212

0

7

1289

439

9018

9018

56

2

8352

EIS

216

0

4

106

2

1129

1129

929

70

0

Appendix D. Study Methodology Synthesis Table
1

2

3

4

5

6

7

8

9

10

11

12

Troponin
Isotype
Troponin
Sensitivity
Analysis Setting

NS

NS

cTn

cTnT

cTnI

cTnI

cTnT

cTnI

Both

cTn

cTnT

cTnT

NS

NS

Standard

High

Standard

Standard

High

High

High

NS

High

Standard

NS

IPH

Lab

ED

PH

PH/ED/IPH

ED/IPH

ED

ED

PH

ED

PH & ED

Inclusion
Criteria

NS

NSTEMI

Typical
Chest
Pain

Typical
Chest
Pain

Typical
Chest Pain

Typical
Chest Pain

Typical &
Atypical
Chest Pain

Typical
Chest Pain

Typical
Chest
Pain

Typical
Chest
Pain

Typical &
Atypical
Chest Pain

Typical
Chest Pain

Exclusion
Criteria

NS

STEMI

NS

STEMI,
CA

STEMI,
Trauma,
Syncope,
CNS, CA,
VT,
AFRVR

Syncope,
dyspnea,
AMS

< 1 value
below 99%
URL

< 18 yrs,
symptoms
> 12 hrs,
CKD

Atypical
Chest
Pain

Symptom
onset > 6
hours

Symptom
onset > 70
minutes

Analysis Interval

NS

NS

Variable

3-4 hrs

15 minutes

NS

up to 6 hr

Pregnancy,
< 18 yrs,
terminal
illness,
interfacility
transfer
2 hr

0,1,2,3, &
6 hrs

NS

0,2,4, & 6
hrs

0 & 2 hrs

Assay Range
Cut-off

NS

NS

99%
URL

99%
URL

99% URL

NS

99% URL

99% URL

99% URL

NS

99% URL

99% URL

1 = Amsterdam, E., et al. (2014), 2 = Khera, S., et al. (2014), 3 = Layfield, C., et al (2015), 4 = Ezokowitz, J, et al. (2015), 5 = Venturini, J, et al. (2013), 6 = Borna, C., et al. (2016), 7 =
Bierner, M., et al, (2015), 8 = Cullen, L, et al, (2013), 9 = Gimenez, M, et al. (2014), 10 = Ishak, M, et al. (2015), 11 = Saad, Y, et al. (2015), 12 = Stengaard, C, et al. (2013).

AMI-Acute Myocardial Infarction, AMS-Altered Mental Status, AFRVR-Atrial Fibrillation with Rapid Ventricular Response, CA-Cardiac Arrest, cTnCardiac Troponin Unspecified, cTnI-Cardiac Troponin I, cTnT-Cardiac Troponin T, CKD-Chronic Kidney Disease, CNS-Central Nervous
Symptomology, ED-Emergency Department, IHP-In-patient Hospitalization, PH-Pre-hospital, NS-Not Specified, NSTEMI-non-ST Segment Elevation
Myocardial Infarction, STEMI-ST Segment Elevation Myocardial Infarction, URL-Upper Reference Limit, VT-Ventricular Tachycardia
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Appendix E. Levels of Evidence Synthesis Table
LEVELS OF EVIDENCE

1

2

3

4

X

X

X

X

5

6

7

8

9

10

Level I: Systematic review or meta-analysis
Level II: Randomized Controlled Trial

X

Level III: Controlled Trial without
Randomization
Level IV: Case-control or Cohort Study
Level V: Systematic Review of Qualitative or
Descriptive Studies

X

X

X

X

X

Level VI: Qualitative or Descriptive Study

1 = Amsterdam, E., et al. (2014), 2 = Khera, S., et al. (2014), 3 = Layfield, C., et al (2015), 4 = Ezokowitz, J, et al. (2015), 5 = Venturini, J, et al. (2013), 6 = Borna, C., et al. (2016), 7 =
Bierner, M., et al, (2015), 8 = Cullen, L, et al, (2013), 9 = Gimenez, M, et al. (2014), 10 = Ishak, M, et al. (2015), 11 = Saad, Y, et al. (2015), 12 = Stengaard, C, et al. (2013).

Appendix F. Outcome Measures Synthesis Table

1
2
3
4
5
6
7
8
9
10

FMC to T1

T1 to T2

T2 to Dx

FMC to Dx

Dx to EIS

MACE

⎯
⎯

⎯


⎯




⎯
⎯
⎯
⎯


⎯


⎯

⎯





⎯


⎯




⎯



















⎯




⎯
⎯


FMC = First Medical Contact, T! = First Troponin, T2 = Second Troponin, Dx = Diagnosis, EIS = Early Invasive Strategy, MACE = Major Adverse Cardiac Events
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Appendix G. Lippitt’s Change Theory
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Appendix H. Prehospital Troponin Logic Model
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